Paper - WANFANG MED ONLINE

You Position: Home > Paper

Gut fungal microorganisms and inflammatory bowel disease

( views:48, downloads:0 )

Author:: No author available

Journal Title:: World Chinese Journal of Digestology

Issue:: 17

DOI:: 10.11569/wcjd.v25.i17.1528

Key Word:: 真菌菌群;炎症性肠病;微生物群失调;微生态制剂;Fungal flora;Inflammatory bowel disease;Microorganism imbalance;Microecological preparations

Abstract： The development of inflammatory bowel disease (IBD) is associated with genetic,environmental,immune,and intestinal microflora.It has been found that IBD is closely related to fungal microflora.Fungi colonizing in the normal intestine are an important component of intestinal microorganisms.IBD patients have imbalanced microbial flora,and abnormal distribution of fungi may be involved in the occurrence or progression of IBD.Stool microbial transplantation and micro-ecological agents have been shown to be effective in the treatment of IBD.However,it is still unclear whether the change of gut fungal microflora in patients with IBD is a secondary event to the imbalance of intestinal bacteria or an independent etiological factor.Here we review the recent progress in the research of the impact of fungal microorganisms on the development of IBD and the potential value of microbial ecological agents in the treatment of IBD.

Reference

[1]余世界,董卫国.炎症性肠病发病机制的研究新进展[J].2014,(2).
[2]任亚方,王琍琍.新生儿肠道细菌定植研究进展[J].2010,(1).
[3]闫一帆,姜敏,孙明军.炎症性肠病与肠道菌群[J].2015,(2).
[4]曾骏成,岑俊威,周宇.炎症性肠病易感基因单核苷酸多态性的研究进展[J].2016,(4).
[5]刘倩.霉菌细胞壁β-葡聚糖对溃疡性结肠炎肠道粘膜免疫的影响[D].2014.
[6]周星璐,潘文胜.炎症性肠病内科治疗进展[J].2013,(16).
[7]郑翠芳,黄瑛.布拉酵母对炎症性肠病的治疗作用[J].2009,(3).
[8]杜慧真.肠道微生态与人体健康[C].2013.
[9]艾静,王承党.遗传与环境因素在炎症性肠病发病机制中的作用研究[J].2014,(2).
[10]姬劲峰,熊丽丽.布拉氏酵母菌应用于肠内营养治疗的效果观察[J].2015,(7).
[11]杨文静,刘占举.肠道菌群失衡在炎症性肠病中的作用[J].2015,(11).
[12]Honda, Kenya,Ivanov, Ivaylo I..Intestinal Commensal Microbes as Immune Modulators[J].2012,12(4).
[13]Z. Kurugöl,G. Koturoğlu.Effects of Saccharomyces boulardii in children with acute diarrhoea[J].2005,94(1).
[14]王子恺,杨云生,孙刚,等.肠道微生物群落与炎症性肠病关系研究进展[J].2013,(11).
[15]Hussey, Mary,Mc Garrigle, Robert,Kennedy, Una,etc.Long-term assessment of clinical response to adalimumab therapy in refractory ulcerative colitis[J].2016,28(2).
[16]Chehoud, Christel,Do, Lindsey G. Albenberg,Judge, Colleen,etc.Fungal Signature in the Gut Microbiota of Pediatric Patients With Inflammatory Bowel Disease[J].2015,21(8).
[17]Falkowski,N.R.,Huffnaglea,G.B.,Kao,J.Y.,etc.Candida albicans and bacterial microbiota interactions in the cecum during recolonization following broad-spectrum antibiotic therapy[J].2012,80(10).
[18]Manichanh,C.,Borruel,N.,Casellas,F.,etc.The gut microbiota in IBD[J].2012,9(10).
[19]叶丹丹,樊萌萌,关琼,等.宏基因组研究的生物信息学平台现状[J].2012,(6).
[20]Dalton,J.P.,Desmond,A.,Shanahan,F.,etc.Detection of Mycobacterium avium subspecies paratuberculosis in patients with Crohn's disease is unrelated to the presence of single nucleotide polymorphisms rs2241880 (ATG16L1) and rs10045431 (IL12B)[J].2014,203(3).
[21]Cammarota, Giovanni,Ianiro, Gianluca,Tilg, Herbert,etc.European consensus conference on faecal microbiota transplantation in clinical practice[J].2017,66(4).
[22]Pascal, Victoria,Pozuelo, Marta,Borruel, Natalia,etc.A microbial signature for Crohn's disease[J].2017,66(5).
[23]Round JL,Mazmanian SK.The gut microbiota shapes intestinal immune responses during health and disease.[J].2009,9(5).
[24]Kane SV,Afif W,Bruining DH,etc.Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease.[J].2010,105(5).
[25]Dinwiddie,D.L.,Bracken,J.M.,Bass,J.A.,etc.Molecular diagnosis of infantile onset inflammatory bowel disease by exome sequencing[J].2013,102(5).
[26]Tang, Vivian,Valim, Clarissa,Moman, Rajat,etc.Assessment of Fecal ASCA Measurement as a Biomarker of Crohn Disease in Pediatric Patients[J].2017,64(2).
[27]Bernard Khor,Agnès Gardet,Ramnik J. Xavier.Genetics and pathogenesis of inflammatory bowel disease[J].2011,474(Jun.16 TN.7351).
[28]牛小娟,许静涌,宋京海.炎症性肠病生物治疗的进展[J].2013,(32).
[29]楚杰,郭刚,刘可春.布拉酵母菌防治肠道疾病的研究进展[J].2013,(4).
[30]Guslandi, Mario.Role of Probiotics in Crohn's Disease and in Pouchitis[J].2015,49(Suppl.1).
[31]Annie, Standaert-Vitse,Thierry, Jouault,Peggy, Vandewalle,etc.Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn's disease.[J].2006,130(6).
[32]Sun L,Nava GM,Stappenbeck TS.Host genetic susceptibility, dysbiosis, and viral triggers in inflammatory bowel disease.[J].2011,27(4).
[33]Wei, Xiaohui,Kenny, Jane R.,Dickmann, Leslie,etc.Assessment of Disease-Related Therapeutic Protein Drug-Drug Interaction for Etrolizumab in Patients With Moderately to Severely Active Ulcerative Colitis[J].2016,56(6).
[34]Tyson R, Chiaro,Ray, Soto,W, Zac Stephens,etc.A member of the gut mycobiota modulates host purine metabolism exacerbating colitis in mice.[J].2017,9(380).
[35]Jürgen, Schulze,Ulrich, Sonnenborn.Yeasts in the gut: from commensals to infectious agents.[J].2009,106(51-52).
[36]Karen L. Madsen,David Malfair,Derek Gray,etc.Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora[J].1999,5(4).